Quick Answer
CHAMPIONS ONCOLOGY, INC. reported R&D Expense of $6.83 million for fiscal year 2025.
CHAMPIONS ONCOLOGY, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.83M | -28.5% |
| 2024 | $9.54M | -17.3% |
| 2023 | $11.54M | +23.2% |
| 2022 | $9.37M | +30.3% |
| 2021 | $7.20M | +22.9% |
| 2020 | $5.85M | +22.0% |
| 2019 | $4.80M | +9.0% |
| 2018 | $4.40M | +2.5% |
| 2017 | $4.29M | +2.4% |
| 2016 | $4.19M | -13.4% |
| 2015 | $4.84M | +113.9% |
| 2014 | $2.27M | +18.0% |
| 2013 | $1.92M | -34.6% |
| 2012 | $2.94M | +0.9% |
| 2011 | $2.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $2.27M | +32.1% | -13.2% |
| October 31, 2025 | $2.62M | +54.9% | +25.6% |
| July 31, 2025 | $2.08M | +43.2% | +21.1% |
| January 31, 2025 | $1.72M | -21.4% | +1.8% |
| October 31, 2024 | $1.69M | -32.8% | +16.2% |
| July 31, 2024 | $1.45M | -47.9% | -33.5% |
| January 31, 2024 | $2.19M | -31.7% | -13.1% |
| October 31, 2023 | $2.52M | -3.4% | -10.0% |
- CHAMPIONS ONCOLOGY, INC. showed a decrease of -28.5% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, CHAMPIONS ONCOLOGY, INC.’s r&d expense has grown by 134.5% (from $2.91 million to $6.83 million).
- The most recent figure is from CHAMPIONS ONCOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: